Biocause Pharma(SZ:000627) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-18 04:22Core Viewpoint - Tianmao Group has voluntarily terminated its stock listing, and shareholders are entitled to cash options based on their holdings [1][3]. Group 1: Stock Suspension and Cash Options - Tianmao Group's stock has been suspended from trading since August 14, 2025, following a resolution passed at the first extraordinary general meeting of 2025 [1]. - Shareholders holding eligible A-shares will receive one cash option for each share held, with a cash option exercise price set at 1.60 yuan per share [1][8]. - The cash option exercise period is from September 15 to September 19, 2025, during specific trading hours [2][11]. Group 2: Conditions for Exercising Cash Options - Eligible shareholders must not have shares that are restricted, frozen, or pledged when exercising cash options [5][12]. - Shareholders must transfer shares from margin accounts to regular accounts before the cash option exercise period [13][14]. - If shareholders do not submit a valid exercise request during the specified period, they will forfeit their cash options [2][20]. Group 3: Cash Option Details - A total of 1,579,130,703 cash options will be distributed to eligible shareholders [8]. - The cash option's value is calculated at 0.15 yuan, with a Delta value of -0.4759, indicating a slight premium of -1.25% compared to the stock's last closing price of 1.58 yuan [10]. - The cash options will not be listed for trading [8]. Group 4: Execution and Settlement Process - The cash option exercise requests must be submitted through the Shenzhen Stock Exchange trading system [11]. - The settlement of exercised cash options will occur on the day following the exercise period, with a full non-guaranteed settlement process [15].